Brief: Kadimastem, NLS Pharmaceutics Announce Effectiveness Of SEC Registration Statement For Proposed Merger
10/09/2025 11:32
Sept 10 (Reuters) - NLS Pharmaceutics NLSP.O: KADIMASTEM AND NLS PHARMACEUTICS ANNOUNCE EFFECTIVENESS OF SEC REGISTRATION STATEMENT IN CONNECTION WITH PROPOSED MERGER Source text: ID:nPn78ntlQa Further company coverage: NLSP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing